Phase 3 Osteoarthritis Trial, Recruiting NCT05992883 Sponsor: Mayo Clinic Condition: Osteoarthritis
Back to Osteoarthritis

Phase 3 Osteoarthritis Trial, Recruiting

NCT05992883
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults over 40 years of age
  • People who have pain at the base of the thumb that is triggered by pressure and movement
  • People whose thumb base pain has not improved with previous treatments such as over-the-counter pain relief (ibuprofen or acetaminophen), ice, splints or braces, or topical pain relief products
  • People whose X-rays or imaging show signs of arthritis at the thumb base, classified under the Eaton-Littler system (stages 1 through 4)
  • People who have read and signed the informed consent form, showing they understand what the trial involves
  • People who are covered by health insurance

Who may not be able to join:

  • People with a known allergy to either of the treatment products used in the trial
  • People whose pain management routine or other symptom treatments for their hand condition were changed within the four weeks before joining the trial
  • People who have arthritis affecting a nearby joint in the wrist area (scaphoid-trapezial arthritis) that is causing symptoms
  • People with a current local or whole-body infection
  • People who have had previous surgery on the thumb being studied
  • People who have had a previous injury to the thumb being studied
  • People who have an inflammatory arthritis condition, such as rheumatoid arthritis or psoriatic arthritis
  • People with severe or poorly controlled high blood pressure
  • People who have a condition called De Quervain tendinopathy affecting the thumb area
  • People who have had an injection into the thumb base joint being studied within the previous 6 weeks
  • People with uncontrolled diabetes
  • People who are pregnant or breastfeeding; women of childbearing potential would need a negative pregnancy test before receiving the injection (women who are not able to become pregnant due to surgical procedures or who are aged 50 or over with at least 12 months without a period may be eligible without needing a pregnancy test — confirm with trial site)
  • People with a weakened immune system
  • People who currently use nicotine products, or who have stopped using them within the last 12 months
  • People who are under legal guardianship or who are not fully independent in decision-making
  • People who are already taking part in another clinical trial that may interfere with this one
  • People who, in the trial investigators' judgement, would be unable to follow the trial requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Marco Rizzo, MD, Mayo Clinic

Phone: 5072939765

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
28 July 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Visual Analogue Scale (VAS) of Pain

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov